A dual-channel self-amplifying lateral flow immunoassay for the on-site ultrasensitive simultaneous detection of salivary cortisol and melatonin
Analytica Chimica Acta · 2025-12 · 1378 · 344697
DOI: 10.1016/j.aca.2025.344697 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytica Chimica Acta, 2025-12. Verfasst von Seonjong Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea. Hauptthemen laut MEDLINE: Melatonin, Hydrocortisone, Saliva. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Gwangju Institute of Science and Technology, National Research Foundation of Korea.
Abstract (Originalsprache)
The on-site simultaneous measurement of cortisol and melatonin is valuable for comprehensively assessing circadian rhythms and understanding their complex interplay under physiological conditions. However, no commercial point-of-care test currently enables the concurrent detection of these salivary hormones. Consequently, there is a significant demand for an on-site, user-friendly diagnostic platform. While the lateral flow immunoassay (LFI) is widely used in point-of-care testing, its sensitivity is insufficient for detecting salivary cortisol and melatonin. To overcome this limitation, the self-amplifying LFI (saLFI) developed previously for salivary cortisol detection, is extended to enable salivary melatonin detection in combination with a gold enhancement method. Two saLFIs are integrated into a single device using a dual-channel sample pad, creating a dual-channel self-amplifying lateral flow immunoassay (2ch-saLFI). This integrated dual-channel sample pad provides an equal distribution of the sample solution to two strips and two self-amplifying complexes. Consequently, the novel 2ch-saLFI enables the simultaneous on-site detection of both hormones from a single sample injection, delivering results within 30 min. The 2ch-saLFI demonstrates a high sensitivity, with detection limits of 5.39 and 0.476 pg mL-1 for cortisol and melatonin, respectively (i.e., below typical physiological levels). Validation using 20 clinical samples provides a strong correlation with standard ELISA methods (R2 = 0.9017 for cortisol and 0.9101 for melatonin). Overall, the 2ch-saLFI represents the first point-of-care test enabling the on-site, simultaneous, and highly sensitive measurement of salivary cortisol and melatonin via a single sample injection. This development allows an affordable clinical assessment of circadian biology for advanced healthcare applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.
- Department of Psychiatry, Chonnam National University Medical School, Gwangju, Republic of Korea.
- Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea; GMD Biotech, Inc., Gwangju, Republic of Korea. Electronic address: mkim@gist.ac.kr.
Förderung
- Gwangju Institute of Science and Technology
- National Research Foundation of Korea
Zitieren
APA
Kim, S., Kang, H. J., Kim, J. M., & Kim, M. G. (2025). A dual-channel self-amplifying lateral flow immunoassay for the on-site ultrasensitive simultaneous detection of salivary cortisol and melatonin. Analytica Chimica Acta, 1378, 344697. https://doi.org/10.1016/j.aca.2025.344697
Vancouver
Kim S, Kang HJ, Kim JM, Kim MG. A dual-channel self-amplifying lateral flow immunoassay for the on-site ultrasensitive simultaneous detection of salivary cortisol and melatonin. Analytica Chimica Acta. 2025;1378:344697. doi:10.1016/j.aca.2025.344697
BibTeX
@article{Kim2025,
author = {Kim, Seonjong and Kang, Hee-Ju and Kim, Jae-Min and Kim, Min-Gon},
title = {A dual-channel self-amplifying lateral flow immunoassay for the on-site ultrasensitive simultaneous detection of salivary cortisol and melatonin},
journal = {Analytica Chimica Acta},
year = {2025},
volume = {1378},
pages = {344697},
doi = {10.1016/j.aca.2025.344697}
}
EUVIMED